TIMP1 and glioblastoma: The engineered minimal TIMP variants, particularly mTC1 and mTC3, exhibit a strong potential for inhibiting GBM cell migration similar to wild-type TIMPs, and this substantial reduction in the migration of T98G and A172 cells highlights their efficacy as potential therapeutic agents for GBM.